Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.

SABCS 2016

6 - 10 Dec 2016

Henry B. Gonzalez Convention Center, San Antonio, United States of America

A phase III study of buparlisib and fulvestrant in HR positive advanced breast cancer

Dr Ruth O'Regan - University of Wisconsin-Madison, Madison, USA

A phase III study of buparlisib and fulvestrant in HR positive advanced breast cancer ( Dr Ruth O'Regan - University of Wisconsin-Madison, Madison, USA )

Five years of letrozole does not improve disease free survival for pretreated HR positive breast cancer

Dr Terry Mamounas - UF Health Center, Orlando, USA

Five years of letrozole does not improve disease free survival for pretreated HR positive breast cancer ( Dr Terry Mamounas - UF Health Center, Orlando, USA )

Reducing chemo-associated hair loss with scalp cooling cap

Dr Julie Rani Nangia - Baylor College of Medicine, Houston, USA

Reducing chemo-associated hair loss with scalp cooling cap ( Dr Julie Rani Nangia - Baylor College of Medicine, Houston, USA )

Decoding breast cancer predisposition genes

Dr Fergus Couch - Mayo Clinic, Rochester, USA

Decoding breast cancer predisposition genes ( Dr Fergus Couch - Mayo Clinic, Rochester, USA )

Macrophage iron recycling in triple negative breast cancer

Dr Lisa Privette Vinnedge - Cincinnati Children's Hospital, Cincinnati, USA

Macrophage iron recycling in triple negative breast cancer ( Dr Lisa Privette Vinnedge - Cincinnati Children's Hospital, Cincinnati, USA )

Results of the BELLE-3 study of buparlisib for advanced breast cancer

Dr Ruth O'Regan - University of Wisconsin-Madison, Madison, USA

Results of the BELLE-3 study of buparlisib for advanced breast cancer ( Dr Ruth O'Regan - University of Wisconsin-Madison, Madison, USA )

Epirubicin and cyclophosphamide before docetaxel in early breast cancer

Dr Bent Ejlertsen - Rigshospitalet Copenhagen, Denmark

Epirubicin and cyclophosphamide before docetaxel in early breast cancer ( Dr Bent Ejlertsen - Rigshospitalet Copenhagen, Denmark )

Matched mutations and long term letrozole for breast cancer

Dr Virginia Kaklamani - UT Health Science Center, San Antonio, USA

Matched mutations and long term letrozole for breast cancer ( Dr Virginia Kaklamani - UT Health Science Center, San Antonio, USA )

neoMONARCH: CDK inhibition for HR positive, HER negative breast cancer

Dr Sara Hurvitz - Ronald Reagan UCLA Medical Center, Los Angeles, USA

neoMONARCH: CDK inhibition for HR positive, HER negative breast cancer ( Dr Sara Hurvitz - Ronald Reagan UCLA Medical Center, Los Angeles, USA )

Oestrogen deprivation inffective with chemo for HR/HER positive breast cancer

Dr Mothaffar Rimawi - Baylor College of Medicine, Houston, USA

Oestrogen deprivation inffective with chemo for HR/HER positive breast cancer ( Dr Mothaffar Rimawi - Baylor College of Medicine, Houston, USA )

No benefit for adjuvant ibandronate at 3 years in early breast cancer

Prof Sabine Linn - Netherlands Cancer Institute, Amsterdam, The Netherlands

No benefit for adjuvant ibandronate at 3 years in early breast cancer ( Prof Sabine Linn - Netherlands Cancer Institute, Amsterdam, The Netherlands )

PARP inhibitory velaparib trialled in BRCA1/2 breast cancer

Dr Heather Han - H. Lee Moffitt Cancer Center, Tampa, USA

PARP inhibitory velaparib trialled in BRCA1/2 breast cancer ( Dr Heather Han - H. Lee Moffitt Cancer Center, Tampa, USA )

Matched mutations in the progression of metastatic breast cancer

Dr Ofir Cohen - Broad Institute of MIT and Harvard, Cambridge, USA

Matched mutations in the progression of metastatic breast cancer ( Dr Ofir Cohen - Broad Institute of MIT and Harvard, Cambridge, USA )

Expert discussion on CDK 4/6 inhibition in breast cancer

Prof Richard Finn, Prof Michael Gnant, Dr Mark Harries and Prof Sandra Swain

Expert discussion on CDK 4/6 inhibition in breast cancer ( Prof Richard Finn, Prof Michael Gnant, Dr Mark Harries and Prof Sandra Swain )

PD-1 therapy with eribulin for triple negative MBC

Dr Sara Tolaney - Dana–Farber Cancer Institute, Boston, USA

PD-1 therapy with eribulin for triple negative MBC ( Dr Sara Tolaney - Dana–Farber Cancer Institute, Boston, USA )

Women experiencing menopause symptoms less likely to adhere to medication

Dr Samuel Smith - University of Leeds, Leeds, UK

Women experiencing menopause symptoms less likely to adhere to medication ( Dr Samuel Smith - University of Leeds, Leeds, UK )

Breast cancer mortality declining globally

Dr Cécile Pizot - International Prevention Research Institute, Lyon, France

Breast cancer mortality declining globally ( Dr Cécile Pizot - International Prevention Research Institute, Lyon, France )

Everolimus extends PFS for HR positive, HER2 negative breast cancer

Dr Noah Kornblum - Montefiore Medical Center, New York, USA

Everolimus extends PFS for HR positive, HER2 negative breast cancer ( Dr Noah Kornblum - Montefiore Medical Center, New York, USA )

TEAM IIb trial results: Adjuvant ibandronate in early breast cancer

Prof Sabine Linn - Netherlands Cancer Institute, Amsterdam, The Netherlands

TEAM IIb trial results: Adjuvant ibandronate in early breast cancer ( Prof Sabine Linn - Netherlands Cancer Institute, Amsterdam, The Netherlands )

Neoadjuvant abemaciclib for HR positive, HER negative breast cancer

Dr Sara Hurvitz - Ronald Reagan UCLA Medical Center, Los Angeles, USA

Neoadjuvant abemaciclib for HR positive, HER negative breast cancer ( Dr Sara Hurvitz - Ronald Reagan UCLA Medical Center, Los Angeles, USA )

TCHP with/out oestrogen for HR/HER positive breast cancer

Dr Mothaffar Rimawi - Baylor College of Medicine, Houston, USA

TCHP with/out oestrogen for HR/HER positive breast cancer ( Dr Mothaffar Rimawi - Baylor College of Medicine, Houston, USA )

Efficacy of veliparib with carboplatin and paclitaxel for BRCA1/2 mutations in metastatic breast cancer

Dr Heather Han - H. Lee Moffitt Cancer Center, Tampa, USA

Efficacy of veliparib with carboplatin and paclitaxel for BRCA1/2 mutations in metastatic breast cancer ( Dr Heather Han - H. Lee Moffitt Cancer Center, Tampa, USA )

Extended adjuvant endrocine therapy with letrozole after aromatase inhibition

Dr Terry Mamounas - UF Health Center, Orlando, USA

Extended adjuvant endrocine therapy with letrozole after aromatase inhibition ( Dr Terry Mamounas - UF Health Center, Orlando, USA )

Whole exome and transcriptome sequencing of resistant ER positive metastatic breast cancer

Dr Ofir Cohen - Broad Institute of MIT and Harvard, Cambridge, USA

Whole exome and transcriptome sequencing of resistant ER positive metastatic breast cancer ( Dr Ofir Cohen - Broad Institute of MIT and Harvard, Cambridge, USA )

PrECOG: Added everolimus extends PFS for HR positive, HER2 negative breast cancer

Dr Noah Kornblum - Montefiore Medical Center, New York, USA

PrECOG: Added everolimus extends PFS for HR positive, HER2 negative breast cancer ( Dr Noah Kornblum - Montefiore Medical Center, New York, USA )

More from ecancer